Patents by Inventor Hartmut Ehrlich

Hartmut Ehrlich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7968293
    Abstract: The present invention provides methods for providing a prognosis of treatment of diseases associated with inflammatory disease of the brain, including MS, e.g., relapsing-remitting multiple sclerosis (RRMS), Alzheimer's disease, and Parkinson's disease using molecular markers that are shown to be overexpressed or underexpressed in patients treated with intravenous immunoglobulins (IVIG). Also provided are methods to identify compounds that are useful for the treatment or prevention of MS, e.g., relapsing-remitting multiple sclerosis (RRMS), Alzheimer's disease, and Parkinson's disease.
    Type: Grant
    Filed: August 11, 2008
    Date of Patent: June 28, 2011
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Birgit Reipert, Hartmut Ehrlich, Hans-Peter Schwarz, Irina Elovaara
  • Publication number: 20110070592
    Abstract: The present invention provides analytical methods for detecting anti-polymer antibody in an individual. The methods involve contacting a sample from the individual with a water soluble polymer-modified carrier and detecting binding of antibody to the water soluble polymer on the water soluble polymer-modified carrier wherein binding is indicative of the presence of antibody to the water polymer-modified polypeptide. Antibody may be detected to water soluble polymers such as polyethylene glycol, polysialic acid, dextran, hydroxyalkyl starch, or hydroxyethyl starch. When antibody to the water soluble polymer polyethylene glycol is to be detected, the carrier is modified with a non-linear polyethylene glycol derivative.
    Type: Application
    Filed: May 25, 2010
    Publication date: March 24, 2011
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A
    Inventors: Christian Lubich, Juergen Siekmann, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich
  • Publication number: 20100189745
    Abstract: The present invention relates, in general, to materials and methods for production of an improved vaccine against influenza virus, wherein the vaccine comprises a reassortant virus having a hemagglutinin gene and a neuraminidase gene from the same influenza A virus subtype or influenza B strain of virus and internal genes from a different influenza A virus subtype or influenza B strain of virus. In one aspect, the HA and NA genes and the internal genes are from a highly pathogenic H5N1 strain of influenza A.
    Type: Application
    Filed: December 16, 2009
    Publication date: July 29, 2010
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.
    Inventors: Otfried Kistner, Falko-Guenter Falkner, Hartmut Ehrlich, Noel Barrett
  • Publication number: 20100173847
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.
    Type: Application
    Filed: December 21, 2009
    Publication date: July 8, 2010
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A., 3B Pharmaceuticals GmbH, Cosmix Molecular Biologicals GmbH
    Inventors: Michael Dockal, Hartmut Ehrlich, Friedrich Scheiflinger, Ulf Reimer, Ulrich Reineke, Thomas Polakowski, Eberhard Schneider
  • Publication number: 20090235369
    Abstract: The present invention relates, in general, to development of non-human transgenic animals expressing a human blood clotting factor, such as Factor VIII, Factor VII, Factor IX and von Willebrand factor. The invention further provides methods of detecting immunogenic events against human blood clotting factor using the transgenic animals described.
    Type: Application
    Filed: December 30, 2008
    Publication date: September 17, 2009
    Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
    Inventors: Maria Sasgary, Maria Schuster, Hans-Peter Schwarz, Birgit Reipert, Gerhard Antoine, Hartmut Ehrlich
  • Publication number: 20090221017
    Abstract: The present invention relates to a cell-based in vitro screening assay for identifying and selecting therapeutic agents that inhibit amyloid r-induced cytotoxicity.
    Type: Application
    Filed: February 25, 2009
    Publication date: September 3, 2009
    Applicants: Baxter International, Inc., Baxter Healthcare S.A.
    Inventors: Katarzyna Olas, Birgit Reipert, Hans-Peter Schwarz, Hartmut Ehrlich
  • Publication number: 20090148463
    Abstract: The present invention provides methods for providing a prognosis of treatment of diseases associated with inflammatory disease of the brain, including MS, e.g., relapsing-remitting multiple sclerosis (RRMS), Alzheimer's disease, and Parkinson's disease using molecular markers that are shown to be overexpressed or underexpressed in patients treated with intravenous immunoglobulins (IVIG). Also provided are methods to identify compounds that are useful for the treatment or prevention of MS, e.g., relapsing-remitting multiple sclerosis (RRMS), Alzheimer's disease, and Parkinson's disease.
    Type: Application
    Filed: August 11, 2008
    Publication date: June 11, 2009
    Inventors: Birgit Reipert, Hartmut Ehrlich, Hans-Peter Schwarz, Irina Elovaara
  • Patent number: 5196322
    Abstract: A method for the recombinant production of zymogen forms of human protein C is described. These zymogen forms differ from native zymogen protein C in their increased sensitivity to activation by thrombin and thrombin/thrombomodulin. DNA compounds, vectors, and transformants useful in the method are also disclosed.
    Type: Grant
    Filed: October 4, 1991
    Date of Patent: March 23, 1993
    Assignee: Eli Lilly and Company
    Inventors: Nils U. Bang, Hartmut Ehrlich, Brian W. Grinnell, S. Betty Yan
  • Patent number: 4992373
    Abstract: A method for the direct recombinant production of activated protein C is described. DNA compounds, vectors, and transformants useful in the method are also disclosed. The method involves transformation and culture of a host cell with a recombinant DNA vector that encodes a protein C molecule in which the activation peptide is replaced with a cleavage sequence for a cell associated protease.
    Type: Grant
    Filed: December 4, 1987
    Date of Patent: February 12, 1991
    Assignee: Eli Lilly and Company
    Inventors: Nils U. Bang, Hartmut Ehrlich, Brian W. Grinnell, S. Richard Jaskunas